4Ghabeshi S, Sharifi Z, Hosseini S M, et al. Correlation between viral load of HBV in chronic hepatitis B patients and precore and Basal core promoter mutations. Hepat Mon,2013,13 (2) : e7415.
5Ly T D, Servant-Delmas A, Bagot S, et al. Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg)assays in detection of HBsAg mutant forms. J Clin Microbiol, 2006,44 (7) : 2321-2326.
6Tangkijvanich P, Sa-Nguanmoo P, Mahachai V , et al. A case- control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellnlar carcinoma. Hepatol Int ,2010,4 (3) :577-584.
7Peng J, Cheng L, Yin B, et al. Development of an economic and efficient strategy to detect HBsAg: application of "gray-zones" in ELISA and combined use of several detection assays. Clin China Acta,2011,412(23-24) :2046-2051.
8La' ulu S L, Roberts W L. The analytic sensitivity and mutant detection capability of six hepatitis B surface antigen assays. Am J Clin Patho1,2006,125 ( 5 ) : 748 - 751.
9Niedre-Otomere B, Bogdanova A, Skrastina D, et al. Recombinant Semliki Forest virus vectors encoding hepatitis B virus small surface and pre-S1 antigens induce broadly reactive neutralizing antibodies. J Viral Hepat,2012,19(9) :664-673.
10Terato K, Do C T, Cuttler D, et al. Preventing intense false positive and negative reactions attributed to the principle of ELISA to re- investigate antibody studies in autoimmune diseases. J Immunol Methods,2014,407 : 15-25.
